about
Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED);...
Read More
30.29
-1.08
(-3.44%)
242.7K
XNAS Volume
XNAS 14 May, 2026 4:00 PM (EDT)
Not Eligible
Expensive Valuation
Technically Moderately Bullish
Oculis Holding AG Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..